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Background: Saquinavir, a protease inhibitor utilized in HIV infection, shows antitumor activity in various
experimental models. In previous studies performed in our laboratory the drug was found to induce a substantial
increase of telomerase activity in normal peripheral blood mononuclear cells. Aim of the present investigation was
to test whether saquinavir was able to increase telomerase activity and the expression of the catalytic subunit of
telomerase, hTERT, in human malignant hematopoietic cells.
Methods: Human Jurkat CD4+ T cell leukaemia cell line was used throughout the present study. The antiproliferative
effect of saquinavir was tested by the MTT assay. Telomerase activity was determined according to the telomeric
repeat amplification protocol. The expression of hTERT mRNA was semi-quantitative evaluated by RT-PCR amplification
and quantitative Real Time PCR. The binding of the transcription factor c-Myc to its specific E-Box DNA binding-site of
hTERT promoter was analyzed by Electophoretic Mobility Shift Assay (EMSA). The amount of c-Myc in cytoplasm and
nucleus of leukemia cells was determined by Western Blot analysis, and c-Myc down-regulation was obtained by siRNA
transfection.
Results: Saquinavir produced a substantial increase of telomerase activity in Jurkat cells in vitro without increasing but
rather reducing target cell proliferation rate. Telomerase up-regulation appeared to be the result of enhanced
expression of hTERT. Saquinavir-mediated up-regulation of hTERT gene was the result of the increased binding of
proteins to the E-Box sequence of the promoter. Moreover, saquinavir amplified the expression of c-Myc especially in
the nuclear cell fraction. The direct influence of saquinavir on this transcription factor was also demonstrated by the
antagonistic effect of the drug on siRNA induced c-Myc suppression. Since c-Myc is the main responsible for hTERT
transcription, these findings suggest that the main mechanism underlying saquinavir-induced telomerase activation is
mediated by c-Myc up-regulation.
Conclusions: Saquinavir augments hTERT expression while inhibiting leukemic cell growth. Experimental evidences
show that this effect is mediated by saquinavir-influenced increase of c-Myc levels. This could have relevance in terms
of enhanced hTERT-dependent tumor cell immunogenicity and suggests new paharmacological approaches
interfering with c-Myc dependent pathways.
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Several protease inhibitors (PI) have been long term FDA-
approved agents for the treatment of human immunodefi-
ciency virus (HIV-1) infection [1]. More recently, these
compounds [2-4] including the NO derivative of saquina-
vir [5,6], have shown noticeable antitumor activity, that is
distinct from their antiviral properties. This finding has
been originated by the observation that patients taking
antiretroviral protease inhibitors showed a lower incidence
of infection-associated malignancies leading to the hy-
pothesis that these drugs could have antineoplastic prop-
erties [7]. Initially this effect was attributed mostly to the
PI-induced immune reconstitution. Actually, we demon-
strated that saquinavir was able to contrast T cell senes-
cence by inducing up regulation of telomerase and an
increased capability to produce IFN-γ following stimula-
tion [8,9].
In nude mice, PIs, such as saquinavir and indinavir were
shown not only to be able to block the development but
also to induce the regression of angioproliferative sarcoma-
like lesions [10]. These neoplasms were originated by pri-
mary human Kaposi sarcoma cells stimulated by basic
fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF). Thereafter, antitumor activity of sa-
quinavir or indinavir was also demonstrated in “viral free”
tumor models, consisting in nude mice bearing human
neoplasias, including highly aggressive lung, breast, colon
and hepatic carcinomas [4]. PIs are capable of targeting
both matrix metalloproteinases [4] and the proteasome
[11]. Moreover, Timeus et al. demonstrated that saquinavir
suppresses imatinib-sensitive and imatinib-resistant chronic
myeloid leukaemia cells [12]. In this case, saquinavir,
showed dose- and time-related anti-proliferative and pro-
apoptotic effects, particularly on the imatinib-resistant lines.
Furthermore, in this experimental model the activity of sa-
quinavir was significantly amplified by combination with
imatinib itself. The direct antitumor effects of saquinavir
was confirmed by McLean et al. [7] who demonstrated how
the drug is able to induce endoplasmic reticulum stress, au-
tophagy, and apoptosis in human ovarian cancer cells
in vitro.
Telomerase is a specialized RNA template/reverse tran-
scriptase enzymatic complex which synthesizes and adds
TTAGGG repetitive nucleotide sequences to the end of
chromosomes compensating for telomeric loss occurring
at each cell replication [13]. Most differentiated somatic
cells deactivate telomerase and undergo telomere shorten-
ing. However, the enzyme is reactivated in stimulated lym-
phocytes and proliferating stem cells, and is constitutively
expressed and functioning in malignant cells that acquire
the “immortal” phenotype. For this reason, human tel-
omerase reverse transcriptase (hTERT) is considered a uni-
versal, although not specific, tumor-associated antigen
[14-16]. Actually, hTERT-derived peptides are presented bymajor histocompatibility complex (MHC) class I alleles to
T lymphocytes and activate a specific immune response
with a potential role in cancer immune therapy. Indeed,
CD8+ cytotoxic T lymphocytes (CTLs) specific for the
hTERT-derived antigenic epitopes lyse hTERT-positive tu-
mors of different origin [16]. These findings identify
hTERT as an important tumor antigen applicable for anti-
cancer vaccine strategies [17].
Previous studies conducted in our laboratory, demon-
strated that saquinavir was able to increase telomerase ac-
tivity in T lymphocytes [8,9], suggesting a role for this PI
against T cell senescence, through telomerase activation.
In the present study we investigated the “in vitro” effect
of saquinavir on telomerase activity of Jurkat CD4+ T leu-
kaemia cells. The results confirmed an anti-proliferative ef-
fect of saquinavir also in this model and pointed out that
the drug was able to up-regulate telomerase activity and
hTERT expression at transcriptional level, most likely
through c-Myc accumulation. Saquinavir-mediated inhib-
ition of cell growth and increase of telomerase activity show
two different aspects of its prospective role in malignant
cell control. In fact, from one side saquinavir possesses dir-
ect tumor suppressive activity and from the other side, it
could be potentially able to increase hTERT-dependent
tumor cell immunogenicity [16,17].
Materials and methods
Cell line and culture condition
Human Jurkat CD4+ T cell leukaemia cell line was
obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA) and was passaged for less
than six months continuously and routinely checked for
mycoplasma contamination. Cell line was cultured at 37°C
in a 5% CO2 humidified atmosphere in RPMI-1640 (Gibco,
Paisley, Scotland, UK), supplemented with 10% heat
inactivated (56°C, 30 min) fetal calf serum (Gibco),
2 mM L-glutamine, and antibiotics (Flow Laboratories,
McLean, VA, USA), hereafter referred to as “Complete
Medium” (CM). Saquinavir was a kind gift from prof. C.F.
Perno (University of Tor Vergata).
MTT assay
50 × 103 Jurkat cells suspended in 100 μl CM in 96-well
tissue culture plates were treated with saquinavir or the
drug vehicle DMSO as control and incubated at 37°C and
5% CO2. After 96 h of culture, 0.1 mg of MTT (in 20 μl of
PBS) was added to each well and cells were incubated at
37°C for 4 h. Cells were then lysed with a buffer
(0.1 ml/well) containing 20% SDS and 50% N,N-
dimethylformamide, pH 4.7. After an overnight incuba-
tion, the absorbance was read at 570 nm using a 3550-UV
microplate reader (Bio-Rad). Inhibition of proliferation of
tumor cells by saquinavir obtained in 3 separated experi-
ments has been expressed in terms of inhibitory
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calculated as previously described [18].
TRAP assay
Telomerase activity was determined according to the telo-
meric repeat amplification protocol [19]. Briefly, telomer-
ase activity was assayed in whole cell extracts. Cell samples
for detection of telomerase activity were collected at the
time intervals indicated in the results. Cells were washed in
PBS and lysed in ice-cold extraction buffer containing
0.5% 3[(cholamidopropyl)-dimethyl-ammonium]-1-propane-
sulfonate, 10 mM Tris–HCl (pH 7.5), 1 mM MgCl2, 1 mM
EGTA, 5 mM β-mercaptoethanol, 0.1 mM [4(2-amino-
ethyl)-benzenesulfonyl fluoride] hydrochloride, and 10%
Glycerol (Sigma). Extracts from 500 Jurkat cells were used
for TRAP assay. TRAP assay was performed in 50 μl of re-
action mixture [20 mM Tris–HCl (pH 8.3), 68 mM KCl,
1.5 mM MgCl2, 1 mM EGTA, 0.05% Tween 20, 0.1 mg of
TS (5’-AATCCGTCGAGCAGAGTT) primer, 0.5 mM T4
gene 32 protein, 10 mM deoxynucleotide triphosphate, 2
units of Taq polymerase (Promega,Madison, WI, USA),
and 2 μCi of (γ-32P)dCTP (3000 CI/mmol; DuPont NEN
Research Products, Boston, MA)]. Each reaction was car-
ried out in a single PCR tube containing 100 ng of CX
oligonucleotide 5’ -(CCCTTTA)3CCCTAA (Biogen, Rome,
Italy), sealed at the bottom of the tube by a wax barrier.
Samples were incubated at 22°C for 20 minutes to allow
telomerase to extend TS primer, followed by a 31-cycle
PCR amplification (Perkin Elmer Corp., Norwalk, CT) of
the telomeric products. Forty μl of the PCR products were
run on 10% non-denaturing acrylamide gels. Gels were
fixed in 0.5 M NaCl, 50% Ethanol, and 40 mM Sodium
Acetate (pH 4.2) and then exposed to X-Ray Film (Kodak,
Rochester, NY) at – 80°C.
The signal intensity of each band was measured and
expressed in optical density (OD). The semi-quantitative
analysis of telomerase activity was performed by adding
the signals of the ladder products in each lane, corrected
for the background.
RT-PCR
The expression of hTERT mRNA was semi-quantitatively
evaluated by RT-PCR amplification as described [20].
Briefly, hTERT mRNA was amplified using the primer
pairs: 5’-CGGAAGAGTGTCTGGAGCAA-3’ and 5’-
GGATGAAGCGGAGTCTGGA-3’ . Total RNA was iso-
lated from the cells using Trizol (Invitrogen) according to
the manufacturer’s protocol, and cDNA was synthesized
from 1 μg of RNA using the cDNA Cycle kit (Invitrogen)
with random primers. Typically, 2 μl aliquots of the
reverse-transcribed cDNA were amplified by 28 cycles of
PCR in 50 μl of buffer [10 mM Tris–HCl (pH 8.3),
2.5 mM MgCl2, and 50 mM KCl] containing 1 mM each
of dATP, dGTP, dTTP, and 32P- dCTP (AmershamBiosciences, Amersham, United Kingdom), 2.5 units of Taq
DNA polymerase (Promega, Madison, Wisconsin), and
0.2 mM primers. Each cycle consisted of denaturation at 94°
C for 30 s, annealing at 60°C for 30 s and extension at 72°C
for 45 s. The PCR products were resolved by electrophoresis
in 7% polyacrylamide gels. The efficiency of cDNA synthesis
from each sample was estimated by PCR using GAPDH
specific primers: 5’ - GAAGGTGAAGGTCGGAGTC-3’and
5’-GAAGATGGTGATGGGATTTC-3’.
Real time PCR
Briefly 2 × 106 viable Jurkat T cells treated or not with sa-
quinavir were harvested after 24 h incubation. Samples
were resuspended in 1 ml Trizol (Ambion) and RNA
samples were extracted according to the manufacturer's
instructions. Two μg of RNA were purified by clearance
of DNA traces using Turbo DNA-free kit (Applied
Biosystems, Life Technologies, Monza, Italy). cDNA was
synthesized using 2 μg of DNA-free RNA and TaqMan
RT kit (Applied Biosystems), according to the manufac-
turer’s instructions. hTERT mRNA was quantitatively
detected by real-time reverse transcription polymerase
chain reaction (RT-PCR). For quantitative real time RT-
PCR 5 μl (i.e. 2 μg) of cDNA/sample was amplified
according to the manufacturer’s instructions (Applied
Biosystems) on a Real-Time Stratagene MX3005P, using
a TaqMan gene expression assay kit (Applied Biosystems,
code # Hs00162669-m1). Levels of hTERT were normal-
ized against GAPDH housekeeping expression (Applied
Biosystems code # 4326317E). All real-time RT-PCR re-
actions were performed in triplicate. Normalized TERT
expression (TERT/GAPDH) was calculated using the
ΔΔCt method according to the supplier’s protocol.
Electophoretic mobility shift assay (EMSA)
The binding of the transcription factor c-Myc to its specific
downstream E-Box DNA binding-site from hTERT
promoter was analyzed by EMSA [21]. In particular
we analyzed the DNA oligonucleotide 5’- TCCTGCT
GCGCACGTGGGAAGCCCT-3’, containing the down-
stream “CACGTG” E-Box sequence localized at position
−34 of hTERT promoter. Nuclear extracts were obtained as
previously described [22] from extracts of 2 × 102 viable
cells. Five micrograms of nuclear proteins/reaction were
incubated with 30 000 cpm of 32P-γ-ATP (Amersham)
end-labeled E-Box oligonucleotide extrapolated from
hTERT promoter. Binding reactions were performed in a
10-μl volume for 20 min at room temperature in a buffer
consisting of 5 mg/ml poly(dI– dC), 10mM Tris–HCl,
50mM NaCl, 0.5mM DDT, 0.5 mM EDTA, 1 mM MgCl2,
4% glycerol, pH 7.5 (Promega). For competition assays,
100-fold molar excess of c-Myc standard oligonucleo-
tide (Promega) was used in the binding reaction (data
not shown).
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acrylamide gel electrophoresis (PAGE) at 4°C. Dried gels
were exposed to X-Ray film (Amersham) at −70°C for
12 h.Western blot
For Western Blot analysis of whole cell extracts, cells were
isolated at times indicated and lysates obtained by sonicat-
ing cells in 50 mM Tris–HCl pH 7.5, 2 mM EGTA, 0.1%
triton X-100 buffer. Cytosol and nuclear extracts were pre-
pared as previously described [22]. Lysates from 2 × 106
cells were separated by gel electrophoresis on 10% sodium
dodecyl sulphate-polyacrylamide gels and transferred to
Hybond-P membranes (Amersham Pharmacia Biotech,
Piscataway, NJ). Membranes were then probed with anti
hTERT (Santa Cruz Biotech Inc.) and anti c-Myc (Cell Sig-
nalling) antibodies following the instructions provided by
the manufacturers. All filters were probed with anti
GAPDH (Santa Cruz) as loading control. Quality of
nuclear extracts was analyzed using anti Histone H1 Ab
(Upstate, Lake Placid, NY, USA). Analysis was performed
using the ECL Plus Western detection kit (Amersham
Pharmacia Biotech).c-Myc siRNA
To inhibit Myc expression we used a siRNA technol-
ogy. The siRNA used were purchased from Qiagen:
Hs_LOC731404_4 (#SI03528896) targeting c-Myc mRNA
and AllStars (#1027280), a nonsilencing siRNA with no
homology to any known mammalian gene, as negative
control. For the transfection procedure, exponentially
growing Jurkat cells were seeded in 24-well plates at a
concentration of 2×105 cells/well in 100 μl CM. Immedi-
ately cells were transfected with siRNA using the
HiPerFect Transfection Reagent (Qiagen), according to a
manufacturer’s specific protocol for Jurkat cells. Briefly,
siRNAs were incubated in serum-free medium with
HiPerFect Transfection Reagent for 10 min at room
temperature. Subsequently, the mixture was added to each
well and incubated for 6 h. Then, 400 μl of complete
medium were added to each well and after 24 h the cells
were treated with the drug for further 24 h. The final con-
centration of each siRNAs in each well was 75 nM.Data analysis and statistics
Band intensity of the experiments was quantified by bi-
dimensional densitometry (Bio-Rad, Richmond, CA). Stat-
istical significance was evaluated using student t-test ana-
lysis. This was performed taking into account the mean
and standard deviation of optical densitometric values
obtained in independent experiments. Differences were
considered significant when p values were less than 0.05.Results
Effect of saquinavir on “in vitro” Jurkat cell growth
Saquinavir has shown dose- and time-related anti-
proliferative and pro-apoptotic effects on different tumors
[3,4]. Graded concentrations of saquinavir (from 3.75 to
15 μM) were added to Jurkat cell suspension as described
in Material and Methods. The effect of saquinavir on
Jurkat cell growth has been evaluated using the MTT
assay, performed after 96 h of incubation with the anti-
retroviral agent. The results obtained from 3 pooled inde-
pendent experiments and shown in Figure 1A, indicate
that the IC 50 was 17.36 μM, with a confidence interval
corresponding to 8.93 and 25.79 μM.
Influence of saquinavir on telomerase activity of Jurkat
cell line
Telomerase is a specialized RNA template-containing re-
verse transcriptase able to compensate for telomeric loss
occurring at each cell replication, which is reactivated in
tumor cells [13]. In previous studies we found that saquin-
avir was able to increase telomerase in T cells [8,9]. Here
we analyzed the effect of saquinavir on telomerase activity
of Jurkat cells after 24, 48 and 72 h of treatment. Based on
the results obtained in terms of cell growth inhibition, we
decided to use the concentration of 15 μM of the agent
throughout the next steps of our study. We found that the
protease inhibitor was able to induce up-regulation of tel-
omerase activity, from 24 h to 72 h of cell exposure
(Figure 1). Similar results were obtained by pooling data
obtained from 3 independent experiments in correspond-
ence of all analyzed time intervals (Figure 1B).
Influence of saquinavir on telomerase catalytic subunit
hTERT expression
A major mechanism regulating telomerase activity in hu-
man cells is transcriptional control of the telomerase
catalytic subunit gene, hTERT [23]. Several transcription
factors, including oncogene products (e.g. c-Myc) and
tumor suppressor gene products (e.g. WT1 and p53), are
able to control hTERT transcription [23]. Experiments were
performed in order to estabilish whether the observed up-
regulation of telomerase activity mediated by saquinavir
was the consequence of an increased expression of the
catalytic subunit hTERT. Therefore, cells were exposed to
saquinavir for 48 h, lysed as described in Material and
Method section and separated by SDS-PAGE. This time
point was chosen after time course experiments were run
in order to determine the best interval for this observation.
Results exposed in Figure 2A show that saquinavir was able
to increase hTERT total level in Jurkat cells. Therefore, it is
reasonable to consider that the up-regulated levels of tel-
omerase activity observed in drug-treated Jurkat cells could
be the consequence of the increased levels of catalytic sub-
unit hTERT. These results were confirmed by pooled data
Figure 1 Effect of saquinavir on cell growth and telomerase
activity. A. After 96 h, of culture MTT assay was performed as
described in “Materials and Methods”, on Jurkat cells treated with
saquinavir 3.75, 7.5 and 15 μM or DMSO as control. Saquinavir
concentration which inhibited significantly cell viability (15 μM,
p < 0,005), was close to the IC50 (i.e. 17. 36 μM, see “Results”
section). The data are represented as percentage cell viability of
the untreated cells. Each bar represents the mean ± SD of
determinations from 3 independent experiments. Asterisk
indicates p < 0.05. B. Representative blot of telomerase activity
(TRAP Assay) of whole cell extracts from 500 viable Jurkat cells
determined 24, 48 and 72 h following treatment with saquinavir.
Graph shows the mean ± SD of OD obtained from pooled results
of the effect of saquinavir (15 μM) on telomerase activity of
Jurkat cell line from 3 separate experiments. All p values were
calculated using Student’s t-test. Asterisk indicates p < 0.05.
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servation was also confirmed at transcriptional level. mRNA
expression of hTERT was analyzed by semi-quantitative
RT-PCR in Jurkat controls and in saquinavir-treated cells.
Twenty-four and 48 hours after stimulation, RNA was
extracted and RT-PCR assay was performed to detect
hTERT mRNA. Saquinavir was able to up-regulate hTERTmRNA expression according to the results obtained in the
experiment illustrated in Figure 2C and in the pooled re-
sults relative to 3 separate experiments (Figure 2D). These
results were further confirmed by quantitative Real Time-
PCR experiments performed after 24 hours following ex-
posure to the drug and illustrated in Figure 2E.
Influence of saquinavir on hTERT transcriptional control
To further elucidate the involvement of a transcriptional
mechanism underlying saquinavir- mediated increase of
telomerase activity, we analyzed the binding of nuclear fac-
tors to the downstream E-Box sequence extrapolated from
hTERT promoter, which is specific for c-Myc, the principal
responsible for transcriptional activity of hTERT gene [21].
Saquinavir treatment was able to increase the binding of
nuclear proteins to the E-Box sequence (Figure 3A). Pooled
data from 3 different experiments confirmed the positive
modulation of saquinavir on the binding to the E-Box por-
tion of hTERT promoter (Figure 3B). To explore the role
of c-Myc in saquinavir-mediated up-regulation of hTERT
transcription, we analyzed the effect of the protease inhibi-
tor on the expression and cellular distribution of the onco-
gene product, principal responsible for hTERT gene
transcription. We found that saquinavir increased c-Myc
expression in the nuclei of saquinavir-treated Jurkat cells
(Figure 3C). This observation strongly supports a role for
this transcription factor in saquinavir mediated up-
regulation of hTERT levels and telomerase activity in Jurkat
cells. Results relative to 3 separate experiments are shown
in Figure 3D.
Role of c-Myc in saquinavir-induced hTERT up-regulation
In order to better understand the role of c-Myc in the
observed saquinavir-induced hTERT up-regulation, we
transfected transiently Jurkat cells with siRNA targeting
c-Myc mRNA. The results shown in Figure 3E point out
that a marked down-regulation of c-Myc protein occurred
in c-Myc silenced cells. On the other hand, combined
treatment of target cells with saquinavir and siRNA re-
stored c-Myc expression to control levels (Figure 3E).
Interestingly, siRNA-mediated inhibition of c-Myc was
followed by a marked decline of hTERT expression, which
was restored by concomitant exposure to saquinavir
(Figure 3E). Pooled results relative to 2 separate siRNA ex-
periments are shown in Figure 3F.
Discussion
The present report shows for the first time that an antiretro-
viral molecule belonging to PIs such as saquinavir, is able to
induce a rapid increase of telomerase activity in malignant
cells of haematopoietic origin, while inhibiting their prolifer-
ative potential. In a number of different biological systems,
telomerase activation is linked to increased cell proliferation
and malignant cell aggressiveness [24]. However, in the case
Figure 2 Effect of saquinavir on hTERT expression. A. Representative experiment showing the effect of saquinavir (15 μM) on hTERT
expression tested on whole cell extracts from 2×106 viable CD4+ Jurkat cells 48 h following treatment (Western Blot). Gel loading control was
based on GAPDH expression. Saquinavir increases hTERT levels in Jurkat cells. B. Graph shows the mean ± SD of the ratio hTERT/GAPDH band
intensity obtained by pooling the results from 3 independent experiments. C. Representative gel showing the effect of saquinavir on hTERT
mRNA in Jurkat cell line, determined after 24 and 48 h of treatment, using RT-PCR. GAPDH was used as internal control. Saquinavir up-regulates
hTERT mRNA transcription. D. Graphs show the mean ± SD of OD for 3 independent RT-PCR experiments. E. Effect of saquinavir on hTERT mRNA
expression of Jurkat cells 24 hours following treatment analysed by quantitative real-time RT-PCR. Levels of hTERT are normalized against GAPDH
housekeeping expression. The graph shows the difference in terms of gene expression working out the Delta Delta CT algorithm between TERT
and the housekeeping GAPDH. Data shown are representative of 2 independent experiments. All p values were calculated using one-way paired
Student’s t-test. Asterisk indicates p < 0.05.
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cell proliferation, but rather cell inhibition. This in accord-
ance with previous findings of other laboratories that
demonstrated antitumor effects of this drug in different
experimental models [3,4,12,25]. The inhibition of tumor
cell growth and the pro-apoptotic effects of saquinavir
have been linked to its suppressive activity on proteosoma
[26], metalloproteases and neoangiogenesis [4]. All these
effects appear to be mainly the consequence of saquinavir-
induced impairment of Akt activation based on molecule
phosphorylation [27].
In previous studies, we have shown that saquinavir is
able to increase telomerase activity of normal peripheral
blood mononuclear cells [8,9]. The present study extends
this observation to Jurkat cells, a T leukaemia cell line. In
the case of MNC, the results indicated that saquinavir in-
creased telomerase activity either non-stimulated, or
stimulated with PHA or with anti-CD3 plus anti-CD28
monoclonal antibodies. In our leukaemia model we re-
vealed that drug-induced telomerase up-regulation was
essentially due to increased expression and activation ofthe reverse transcriptase component (i.e. hTERT) of the
enzyme complex. This has been found in terms of either
increased hTERT mRNA and protein level. The mechan-
ism underlying this effect appears to be related to the acti-
vation of hTERT gene promoter revealed by the increased
binding of nuclear extracts of Jurkat cells to the E-Box se-
quence of the promoter, 24 h after exposure to saquinavir,
as shown by EMSA analysis illustrated in Figure 3A. Previ-
ous studies performed by Furuya et al. [28], showed that
survivin up-regulates hTERT expression through a cascade
of intracellular signals starting from activation of Aurora B
kinase that phosphorylates c-Myc which, in turn, in associ-
ation with phosphorylated SP1, binds and activates hTERT
promoter. In our hands, saquinavir was found to increase
the expression of c-Myc, especially in the nuclear fraction of
drug-treated Jurkat cells, thus suggesting that this could be
at least one of the biochemical events responsible of tel-
omerase activation. No data are presently available to ascer-
tain whether saquinavir is involved in survivin circuit with
activating function. However, this hypothesis does not find
support from other investigations that demonstrated that
Figure 3 Role of c-Myc in saquinavir activity. A. Representative gel showing the binding of nuclear extracts of Jurkat cells to the
oligonucleotide 5’- TCCTGCTGCGCACGTGGGAAGCCCT-3’, containing the downstream “CACGTG” E-Box sequence localized at position −34 of
hTERT promoter, 24 h following exposure to saquinavir determined using EMSA. Saquinavir up-regulates the binding of nuclear proteins to the
E-Box sequence. B. Graph shows the mean ± SD of the OD obtained from 3 EMSA independent experiments. C. Representative experiment
showing the effect of saquinavir on c-Myc transcription factor expression tested on nuclear and cytoplasmic extracts of 2×106 viable Jurkat cells
after 24 h of treatment (Western Blot). Quality of nuclear extracts was tested using anti Histone H1 Ab. D. Graphs show the mean ± SD of c-Myc
OD values obtained from 3 experiments of and all p values were calculated using Student’s t-test. E. Representative experiment showing the role
of c-Myc on saquinavir-mediated hTERT up-regulation. Jurkat cells were transfected with siRNA targeting c-Myc mRNA as described in Material
and Methods. c-Myc silencing induces marked down-regulation of c-Myc protein and hTERT which is a target of the transcriptional factor.
Saquinavir restores c-Myc and hTERT expression to control levels. F. Pooled results relative to 2 separate experiments of c-Myc silencing. Asterisk
indicates p < 0.05.
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press rather than activate survivin expression. More attract-
ive is presently the hypothesis that, saquinavir-mediated
up-regulation of c-Myc expression, could be the conse-
quence of drug-induced proteosoma impairment [26],
resulting in the failure of c-Myc protein degradation [31]. In-
deed, the drug is able to reverse also the decline of c-Myc
protein following siRNA- mediated “knock down”. In line
with this hypothesis, beside to a c-Myc mediated increase
of hTERT transcription, we cannot rule out also that reduc-
tion of protein degradation could be partially involved in
saquinavir-induced hTERT up-regulation.
Of particular interest is the finding that saquinavir-
induced telomerase increase was followed by increased pro-
liferation rate in activated normal mononuclear cells [9].
On the contrary, as shown in the present study, cell growth
impairment occurred when Jurkat leukemia cells were
subjected to similar experimental conditions. No data are
presently available to identify the mechanism underlying
the different responses to saquinavir between normal and
malignant lymphoid cells. It is reasonable to assume thattelomerase activity and cell proliferation can be disjointed
processes differentially regulated in different types of cells.
For example, dichotomy between telomerase activity and
proliferation was demonstrated in highly differentiated
“old” CD8+T cells following PDL-1 signalling blockade [32].
In any case, the finding that saquinavir is able to augment
telomerase activity could be considered a negative aspect
of the pharmacological profile of this molecule in oncology.
However, high levels of telomerase are constitutively
expressed in the majority of malignant cells (reviewed in
13). Therefore, increase of telomerase expression should not
modify substantially the already “immortal” phenotype pro-
duced by the basal levels of this enzyme complex in cancer
cells [33]. On the other hand, large experimental evidence is
now available showing that hTERT could be involved in
host’s immune responsiveness against autochtonous tumor.
A number of HLA-restricted peptides can be generated fol-
lowing proteosomal-mediated degradation of hTERT pro-
tein. These peptides, presented by Class I HLA molecules
on malignant cell surface elicit CD8+ T cell cytotoxic re-
sponse of the host, leading to potentially efficient antitumor
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hypothesize that drug-induced up-regulation of hTERT
could increase the probability of endocellular generation of
hTERT-derived peptides showing the molecular pattern re-
quired for presentation in association with class I HLA gene
products on the cell membrane of neoplastic cells. This
would enhance, at least in principle, the level of host’s im-
mune cytotoxic responsiveness against malignant cells. In
fact, a similar mechanism has been found to take place with
other tumor-associated antigens, such as CEA [34,35] or
Thymidilate synthase [36] under the effect of 5-fluorouracil.
However, observations showing that saquinavir could en-
hance c-Myc and possibly hTERT protein expression at
least in part through proteasome activity inhibition seem to
contrast the hypothesis that this agent could increase target
cell immunogenicity. In fact, the presence of large amounts
of immunogenic peptides requires substantial protein deg-
radation via ubiquitin-proteasome system. Nevertheless, it
is reasonable to assume that drug-induced protein accumu-
lation could be followed by a “rebound” phenomenon, with
augmented hTERT degradation and increased levels of
hTERT-derived immunogenic peptides in target cells upon
saquinavir withdrawal. Indeed, this type of antigen presen-
tation kinetics is currently under investigation in our
laboratory.
The observation that saquinavir increases c-Myc levels is
in line with the finding that the drug is able to induce
apoptosis [7,11]. Actually, c-Myc possesses a crucial func-
tion in controlling cell growth, differentiation and apop-
tosis, while its abnormal expression is associated with
many tumors. Overexpression of c-Myc has been shown to
sensitize tumor cells to apoptosis by amplifying the intrin-
sic mitochondrial pathway and by triggering the death re-
ceptor pathways by a variety of stimuli [37]. Therefore an
hypothesis is that the intracellular accumulation of possibly
polyubiquinated c-Myc following the saquinavir-mediated
inhibition of the proteasome, could contribute to explain
the mechanism underlying the apoptosis observed in dif-
ferent tumor cell models treated with the protease
inhinibitor [7,11] and is currently under investigation.
Conclusions
In conclusion, the present report shows for the first time
that saquinavir is able to increase telomerase activity in
leukaemia T cells, thus extending a similar finding previ-
ously obtained by us in normal haemopoietic cells to the
area of haemato-oncology. Moreover, this study indicates
c-Myc as molecular target of saquinavir, suggesting new
perspectives in the pharmacological applications of PIs.
On the other hand, in accordance with previous reports
showing antitumor activity of saquinavir, we confirmed
that the drug does not enhance but rather inhibited the
growth of leukaemic cells. Therefore, saquinavir appears
to play an attracting role as a potential antitumor agent,since along with its inhibiting effect on cell proliferation
it could provide a novel strategy for increasing malignant
cell immunogenicity.
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